When Retinoid or Dapsone Therapy for Lupus Tumidus Has Not Achieved Disease Control

Clinical Scenario

This protocol addresses lupus tumidus in the absence of severe or disseminated cutaneous lupus erythematosus skin lesions, in patients whose prior systemic therapy has not produced an adequate response.

Prior Therapy — Failure Condition

The previous treatment line used retinoids (acitretin or isotretinoin) or dapsone, preferably in combination with antimalarial drugs. Escalation to this protocol is indicated when response to retinoids has not been achieved within 2–6 weeks, or when systemic treatment efficacy could not be established after 3–6 months of evaluation.

Next-Line Approach

This protocol introduces a mycophenolate-based agent as the next step, generally preferred in combination with antimalarial drugs.

The complete dosing sequence, escalation criteria, and monitoring parameters are contained in the full protocol.

Goal: improvement of cutaneous lupus erythematosus disease activity, evaluated after 3–6 months of treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

MMF is suggested as third-line therapy for refractory CLE lesions, preferably in combination with antimalarial drugs.

MPA is suggested as an alternative treatment for MMF.

It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).

View source ↗